ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO833

B Cell and Monocyte Phenotyping in IGA Nephropathy: A Quick Asset to Investigate the Immune Status in Patients with IGA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Sendic, Senka, Karolinska Institutet, Stockholm, Sweden
  • Mansouri, Ladan, Karolinska Institutet, Stockholm, Sweden
  • Lundberg, Sigrid, Danderyd Hospital, Stockholm, Sweden
  • Nopp, Anna, Karolinska Institutet, Stockholm, Sweden
  • Jacobson, Stefan H., Danderyd Hospital, Stockholm, Sweden
  • Lundahl, Joachim, Karolinska Institutet, Stockholm, Sweden
Background

IgA nephropathy (IgAN) is the most common glomerulonephritis. Naive and adaptive immune cells play a major role in the development and progression of disease, therefore unraveling a correlation between changes in the immune status of the patient and clinical outcomes is of great value. We aimed to investigate B cell and monocyte phenotype, comparing the IgAN patients with disease controls (patients with polycystic kidney disease) and healthy individuals.

Methods


IgAN patients (n = 13) were recruited from Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. Patients (men 46%,) with median age of 45 years (IQR 38-60), median eGFR of 57 ml/min x1.73m2 (IQR 42-84) and median urine albumin-to-creatinine ratio of 74 mg/mmol (IQR 18-116). Disease controls with polycystic kidney disease (n=13) were matched for eGFR, gender- and age (±10 years). Healthy controls (n = 13) were gender- and age-matched (±5 years) with patients. CD3+ cells were isolated from freshly separated peripheral blood mononuclear cells by positive selection using a magnetic cell sorting system. CD3+ and CD3- cells were then divided and stained for different subsets of B cells and analyzed by flowcytometry. Cytokines were analyzed by ELISA.

Results

We report an increase in the proportion of CD14+ CD16++ cells (non-classical monocytes) in patient with IgAN comparing to healthy individuals and disease controls. Decrease in the proportion of CD19+ CD27+ IgD+ cells (pre switched B), CD19+ CD27+ CD38+ cells (plasmablasts) in the peripheral circulation of IgAN patients. IgAN and disease control showed an increase in CD19- CD27hi CD38 hi (transitioned plasma cells). We report a higher proportion naïve/pre switched in IgAN patients compared to healthy- and disease controls. We report significantly higher IL-6 in IgAN compared to helathy controls.

Conclusion

The decrease in the number of circulatory pre-switched B cells and plasmablasts, but an increase of transitioned plasma cells in our study suggests trafficking of subsets of B cells in IgAN patients between peripheral blood and extravascular lymphoid tissues. The increase in the proportion of inflammatory monocytes in IgAN patients may play a role in the high inflammatory state and possible crosstalk between different sectors of the immune system through the IL-6 axis.